• About
    • Our Mission
    • Threat of AMR
    • Access and Appropriate Use Principles
    • Our Investors
  • Team
  • Investments
    • How We Invest
    • Our Portfolio
    • Get On Our Radar
  • News
  • Connect
  • All
  • In the News
  • Press Releases
  • Media
June 3, 2024
In the News

Stat News Op-Ed: Antibiotic Innovation is Ailing. 'Brain Drain' May Kill It.

Read More +
May 31, 2024
In the News

American Chemical Society: New Antibiotics Are Hard to Come By. Red Tape is Making the Problem Worse.

Read More +
May 7, 2024
In the News

Los Angeles Times: A Mother's Loss Launches a Global Effort to Fight Antibiotic Resistance

Read More +
April 24, 2024
In the News

The New York Times: F.D.A. Approves Antibiotic for Increasingly Hard-to-Treat Urinary Tract Infections

Read More +
April 24, 2024
Press Releases

AMR Action Fund Portfolio Company UTILITY Therapeutics Granted FDA approval for pivmecillinam

Read More +
February 6, 2024
In the News

Martin Heidecker Offers Insights for Investors in Antimicrobial R&D in New White Paper

Read More +
January 4, 2024
In the News

Harvard Public Health Op-Ed: Tracking Superbugs in the Wake of War

Read More +
December 12, 2023
In the News

Duke-Margolis Center for Health Policy Webinar: “Improving Regulatory Practices to Sustain Antibiotic Innovation”

Read More +
Previous page Next page
contact-bg-img

Connect With Us

Contact
footer_logo

Enabling
Breakthroughs in
Antimicrobials

Stay connected

Stay up-to-date on our work to bring 2 to 4 new antibiotics to patients by the end of the decade. When we have news, we will let you know.

  • About
  • Team
  • Latest
  • Threat of AMR
  • Connect
  • Investments
  • Japan Disclaimer
  • Privacy Policy